Introduction {#sec1-1}
============

Thyroid carcinoma is one of the most common malignancies encountered, showing a progressive trend with an incidence rate of 3.9% in females to 1.3% in males.\[[@ref1]\] Unless the distant metastases are present, it can be treated with an excellent prognosis.\[[@ref2]\] Most thyroid cancer patients are in either euthyroid or hypothyroid state. However, thyrotoxicosis can also be seen in association with thyroid cancer.\[[@ref3]\] Follicular carcinoma thyroid is the most common variant associated with functioning thyroid cancer leading to thyrotoxicosis. Thyrotoxicosis in these patients can be morbid, due to the presence of symptoms such as palpitations, anxiety, tremors, and hyperdefecation. Hence, alleviation of symptoms of thyrotoxicosis is very important along with a reduction in tumor burden to improve the quality of life.

Case Report {#sec1-2}
===========

A 63-year-old woman initially presented with a neck swelling, of 25 years duration, which was progressively increasing in size for 3 years. There was no history of dyspnea, dysphagia, or hoarseness of voice. On ultrasonography, there was a large hypoechoic nodule of size 13 cm × 6.2 cm × 11.6 cm replacing the right lobe of the thyroid, with areas of heterogeneous cystic and calcific foci. Fine-Needle Aspiration Cytology revealed follicular variant of papillary carcinoma thyroid, following which, the patient underwent total thyroidectomy. Post total thyroidectomy histopathological examination (HPE) was suggestive of follicular variant of papillary carcinoma thyroid (pT2NxMx).

Post-thyroidectomy, diagnostic radioiodine I-131 whole body scan (WBS) revealed multiple radioiodine avid lung and bone metastases with no evidence of iodine-avid residual thyroid tissue in the neck \[[Figure 1](#F1){ref-type="fig"}\]. The patient was advised high dose radioactive iodine (HDRAI) therapy but defaulted for treatment. After 2 years, the patient presented with a headache, soft-tissue swelling in the right frontal bone and thyrotoxic features of weight loss, palpitations, and anxiety. Surgical excision of the frontal swelling was performed. Postoperative HPE was suggestive of papillary carcinoma thyroid deposits. Clinical examination revealed a high pulse rate of 112/min, irregular rhythm, normal volume pulse with no radio radial delay or radio femoral delay. The patient also had tremors, increased perspiration and a staring look with prominent eyes. Biochemical parameters were total T3-380 ng/dl, total T4-14.8 μg/dl, thyroid-stimulating hormone (TSH)-0.03 mIU/L, Tg \> 481 ng/ml and antiTg was 1.0 IU/L. In view of high Tg levels, I-131 WBS was done which revealed, multiple radioiodine avid cervical lymph nodes, lung, and skeletal metastases \[[Figure 2](#F2){ref-type="fig"}\]. 200 mci of HDRAI therapy was administered orally. Vitals were monitored regularly. PostHDRAI therapy scan revealed good localization of radioiodine in thyroid bed, lymph nodal, lung, and skeletal metastases \[[Figure 3](#F3){ref-type="fig"}\]. In view of high spinal instability score at D9, D10 vertebral lesions, she was advised for radiotherapy and zoledronate. Hormonal suppression treatment with thyroxine 200 mcg was given. On follow-up after 6 months, her thyrotoxic features subsided with serum TSH-0.03 mIU/L, T3-0.5 ng/ml, and T4-12.3 μg/dl.

![Low dose I-131 whole-body scan showing evidence of radioactive iodine-avid foci in right frontal bone, lungs with no residual radioactive iodine avid tissue in thyroid bed. Physiological concentration seen in urinary bladder region](IJNM-34-134-g001){#F1}

![Low dose I-131 whole-body scan showing evidence of radioactive iodine-avid multiple cervical lymph nodal, bilateral lung, right frontal bone and right pelvic bone metastases. Physiological radiotracer concentration seen in urinary bladder region](IJNM-34-134-g002){#F2}

![Post 200 mCi high-dose radioactive iodine-131 scan showing tracer concentration in right frontal bone, thyroid bed, cervical lymph nodes, bilateral lungs, multiple bilateral ribs, thoracic vertebrae and pelvic bones](IJNM-34-134-g003){#F3}

Discussion {#sec1-3}
==========

Thyrotoxicosis in the setting of differentiated thyroid cancer (DTC) due to functioning metastases has a prevalence rate of 3.38%.\[[@ref4]\] Four clinical settings in which thyroid cancer association seen with thyrotoxicosis are:

The first most frequently encountered association is, an incidentally detected papillary microcarcinoma on HPE in patients, who underwent total thyroidectomy for toxic multinodular goiter, Graves' disease or an autonomous functioning thyroid nodule\[[@ref3]\]Trophoblastic tumors such as benign hydatiform mole or malignant choriocarcinoma due to functioning extrathyroidal tissue\[[@ref5]\]Metastatic infiltration of thyroid from a pancreatic, breast malignancy or malignant lymphoma\[[@ref6]\]Autonomous thyroid cancer metastases.\[[@ref3]\]

Follicular carcinoma thyroid is more commonly associated with functional metastases than mixed papillary-follicular or pure follicular carcinoma. In these patients, all the clinical manifestations of thyrotoxicosis are seen except for dysthyroid eye disease.\[[@ref3][@ref7]\] Measurement of free T3 (FT3) and free T4 (FT4) is important, because these patients may develop isolated T3 or T4 toxicity. Hence when a patient is presenting with thyrotoxicosis, the possibility of malignancy should not be neglected.

Functioning metastases post thyroidectomy in a DTC, can be explained by the following mechanisms:

Combination of TSH receptor and K-ras mutations\[[@ref8]\]A study by Salvatori *et al*. showed that long-acting thyroid stimulators (LATS) promotes the growth of metastatic thyroid cancer cells by stimulating TSH receptors.\[[@ref7]\]

Criteria have been given to diagnose hyperthyroidism in the metastatic setting:

Failure of hyperthyroidism to resolve after adequate thyroidectomyDemonstration of radioiodine uptake by metastatic lesionsExclusion of hyperfunctioning diffuse or nodular thyroid glandLow or absent thyroid radioactive iodine uptake.\[[@ref7][@ref9]\]

All the above criteria were met in the current case. The treatment in such patients is challenging as treatment should be aimed at thyrotoxicosis and thyroid cancer simultaneously. As the thyroid cancer metastases in our case are radioiodine avid, the cornerstone of therapy is HDRAI ablation. However, transient accentuation of thyrotoxicosis may occur following RAI therapy. Hence, pretreatment with antithyroid medication is recommended for severely toxic patients with the poor clinical condition.\[[@ref10]\] Sole treatment with high dose antithyroid drugs in frequent intervals is inefficient in improving the clinical as well as the curative outcome. It has also been documented that, in patients with thyrotoxicosis due to increased basal metabolic rate, the iodine metabolism is increased, thereby rendering the RAI therapy inefficient and requiring more doses when compared with normal thyroid cancer patients.\[[@ref11]\] Post-HDRAI therapy, the patient was kept on hormone suppressive therapy with thyroxine, to reduce the TSH levels which can proliferate the tumor leading to recurrence. Hormone suppressive therapy should be done with caution in these patients, as it could lead to thyrotoxic storm. To reduce the tumor proliferation and to control thyrotoxicosis simultaneously is an uphill task.

Conclusion {#sec1-4}
==========

Neoplastic hyperthyroidism is not a rare entity. Hence, a watchful insight should be present whenever there is a high Tg level or there is an increase in TSH during suppressive therapy. High dose RAI remains the mainstay of treatment to reduce the tumor burden and thereby thyroxine secretion. The prognosis in such patients principally depends on the extent of metastatic disease.
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